Skip to main content

Table 2 Risk of myocardial infarction, stroke, heart failure, and mortality according to fatty liver index

From: The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study

 

Event

Duration (person-years)

Incidence Ratea

Hazard Ratio (95% CI)

Model 1

Model 2

Myocardial infarction

 FLI < 30

898

325,568

2.76

1 (Ref)

1 (Ref)

 30 ≤ FLI < 60

1110

379,063

2.93

1.05 (0.96–1.14)

1.08 (0.99–1.19)

 FLI ≥ 60

1071

361,981

2.96

1.21 (1.10–1.33)

1.28 (1.14–1.44)

 P for trend

   

 < 0.001

 < 0.001

Stroke

 FLI < 30

1305

324,031

4.03

1 (Ref)

1 (Ref)

 30 ≤ FLI < 60

1626

377,182

4.31

1.10 (1.03–1.19)

1.22 (1.13–1.33)

 FLI ≥ 60

1307

360,875

3.62

1.17 (1.08–1.26)

1.41 (1.28–1.56)

 P for trend

   

 < 0.001

 < 0.001

Heart failure

 FLI < 30

2030

324,207

6.26

1 (Ref)

1 (Ref)

 30 ≤ FLI < 60

2097

378,517

5.54

0.92 (0.86–0.97)

0.93 (0.87–0.99)

 FLI ≥ 60

1976

361,310

5.47

1.16 (1.09–1.24)

1.17 (1.07–1.26)

 P for trend

   

 < 0.001

 < 0.001

Mortality

 FLI < 30

3369

328,244

10.26

1 (Ref)

1 (Ref)

 30 ≤ FLI < 60

2822

382,618

7.38

0.74 (0.70–0.78)

1.02 (0.96–1.07)

 FLI ≥ 60

2274

365,317

6.22

0.81 (0.77–0.86)

1.41 (1.32–1.51)

 P for trend

   

 < 0.001

 < 0.001

  1. Model 1: Adjusted for age and sex
  2. Model 2: Adjusted for age, sex, smoking status, alcohol consumption, regular exercise, income, body weight, hypertension, dyslipidemia, fasting glucose, and number of oral hypoglycemic agents used
  3. CI, confidence interval; FLI, fatty liver index
  4. aIncidence per 1000 person-years
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840